RxDoctor Payments Data

Roya Rakhshani, MD

Obstetrics & Gynecology · Costa Mesa, CANPI 1962414003

Payments from drug & device makers

$3,934in general payments, 2019–2025

Across 121 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Acessa Health Inc.$788
  • Sumitomo Pharma America, Inc.$336
  • Astellas Pharma US Inc$263
  • Hologic Sales And Service, LLC$208
  • Mayne Pharma Commercial LLC$154
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$66517%
  • Food & beverage$3,05678%
  • Education$2135%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,934 in reported general payments places this provider in the 85th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$64,592
Medicare patients
219
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated45$22,265
MyrbetriqMirabegron12$15,562
Estradiol69$8,211
Estradiol (Twice Weekly)Estradiol45$5,167
ProgesteroneProgesterone, Micronized40$1,950
DottiEstradiol17$1,682
ValacyclovirValacyclovir Hcl27$1,437
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet13$847
LyllanaEstradiol15$675
Metronidazole13$493
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip37$454
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$295
Medroxyprogesterone Acetate17$122
Zolpidem Tartrate11$100
Citalopram HbrCitalopram Hydrobromide15$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$69$22,26545 claims
Astellas Pharma US IncMyrbetriq$263$15,56212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Costa Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →